Barinthus Biotherapeutics plc (BRNS) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BRNS Revenue Growth
Revenue Breakdown (FY 2024)
BRNS's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
BRNS Revenue Analysis (2019–2025)
As of May 8, 2026, Barinthus Biotherapeutics plc (BRNS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, BRNS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $44.7 million in 2022.
Revenue diversification analysis shows BRNS's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IMCR (+15.6% YoY), ADCT (+4.4% YoY), and NVAX (-52.5% YoY). Compare BRNS vs IMCR →
BRNS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BRNSCurrent | $0 | - | - | - | |
 IMCR | $298M | +15.6% | +58.1% | -11.3% | |
 ADCT | $81M | +4.4% | - | -133.2% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% |
BRNS Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-5,858,659 | - | $-54,194,349 | - |
| 2024 | $15.0M | +1766.5% | $15.0M | 100.0% | $-67,970,000 | -454.1% |
| 2023 | $802K | -98.2% | $802K | 100.0% | $-83,914,000 | -10463.1% |
| 2022 | $44.7M | +16580.2% | $44.7M | 100.0% | $-4,041,000 | -9.0% |
| 2021 | $268K | -94.4% | $268K | 100.0% | $-45,221,000 | -16873.5% |
| 2020 | $4.8M | -29.6% | $-9,566,000 | -198.4% | $-20,046,000 | -415.8% |
| 2019 | $6.8M | - | $-22,997,305 | -336.0% | $-25,664,672 | -374.9% |
See BRNS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BRNS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BRNS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBRNS — Frequently Asked Questions
Quick answers to the most common questions about buying BRNS stock.
Is BRNS's revenue growth accelerating or slowing?
BRNS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is BRNS's long-term revenue growth rate?
Barinthus Biotherapeutics plc's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is BRNS's revenue distributed by segment?
BRNS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.